Cite
HARVARD Citation
Veereman, G. et al. (n.d.). P062 DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB OR COMBINATION THERAPY WITH ORIGINATOR INFLIXIMAB AND IMMUNOMODULATORS SIGNIFICANTLY INCREASES RISK FOR SERIOUS ADVERSE EVENTS IN PEDIATRIC IBD – THE DEVELOP EXPERIENCE. Inflammatory bowel diseases. pp. S29-S30. [Online].